# US 2025/0152586 A1 · Pharmaceutical composition for relieving or treating pain by regulating cerebellar glial cells and method for relieving or treating pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152586 A1
- Document ID: US20250152586A1
- Status: Published application
- Kind: A1
- Application number: 18/720,471
- Filed: 2022-12-13
- Published: 2025-05-15
- Earliest claimed: 2021-12-16
- Assignees: Seoul National University R&Db Foundation; University-Industry Cooperation Group of Kyung Hee University
- Applicants: Seoul National University R&DB Foundation; University-Industry Cooperation Group of Kyung Hee University
- Inventors: Sang Jeong KIM; Sun Kwang KIM; Seung Ha KIM
- Web page: https://patentgrep.com/patent/US20250152586A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/42: Oxazoles
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61N 1/36071: {Pain}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 15/1138: {against receptors or cell surface proteins}
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- C12N 2310/531: Stem-loop; Hairpin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a composition for relieving or treating pain, a method for relieving or treating pain by using same, and a method for screening for a pain-relieving substance. It has been confirmed that pain can be relieved by regulating the cerebellum, whose role in pain has not been known so far, by using the pharmaceutical composition and the method for relieving pain, according to the present invention. Therefore, the cerebellum can be used as a new treatment target for pain relief through the pharmaceutical composition and the method for relieving pain, according to the present invention. It has also been confirmed that, even when the cerebellum is used as a target for pain according to the present invention, there is no impact on motor function. Thus, the pharmaceutical composition and the method can be effectively used in practice in relieving or treating pain.

## Claims

### Claim 1

A method for relieving or treating pain, the method comprising administering a pharmaceutical composition comprising one or more from the group consisting of an inhibitor of the axon terminals of neurons in the locus coeruleus, an inhibitor of receptors of noradrenaline secreted from the axon terminals of neurons in the locus coeruleus, an inhibitor which inhibits the expression of cerebellar glial cell-specific alpha-1 adrenergic receptors, an inhibitor of calcium activation in cerebellar glial cells, and a GABAA receptor agonist; or
an electronic medicine comprising an electrical signal generating unit that generates an electrical signal for pain relief, wherein the signal is a signal that inhibits (i) the axon terminals of neurons in the locus coeruleus, (ii) receptors of noradrenaline secreted from the axon terminals of neurons in the locus coeruleus, (iii) cerebellar glial cell-specific alpha-1 adrenergic receptors, and (iv) cerebellar glial cells;
to an individual in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition exhibits one or more activities selected from the group consisting of the following (i) to (iv):
(i) inhibition of the axon terminals of neurons in the locus coeruleus;
(ii) inhibition of adrenergic receptors to interfere with the action of noradrenaline secreted from the axon terminals of neurons in the locus coeruleus on cerebellar glial cells;
(iii) inhibition of calcium activation in cerebellar glial cells; and
(iv) inhibition of the cerebellar nuclei, a subpathway for the activation of cerebellar glial cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pain is neuropathic pain, acute pain, neurogenic pain, or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitor or receptors of noradrenaline is an alpha-1 adrenergic receptor inhibitor (alpha-1 adrenergic blocking agent).

### Claim 5 (depends on 4)

The method of claim 4, wherein the alpha-1 adrenergic receptor inhibitor (alpha-adrenergic blocking agent) is a substance that inhibits the expression or activity of cerebellar glial cell-specific alpha-1 adrenergic receptors, and the inhibitor is one or more selected from the group consisting of small interference RNA (siRNA), short hairpin RNA (shRNA), microRNA (microRNA), a ribozyme, a DNAzyme, a peptide nucleic acid (PNA), an antisense oligonucleotide, and an antibody.

### Claim 6 (depends on 5)

The method of claim 5, wherein the alpha-1 adrenergic receptor inhibitor comprises shRNA consisting of SEQ ID NO: 1.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitor of receptors of noradrenaline is prazosin, and
the GABAA receptor agonist is muscimol.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises a physiologically acceptable carrier.

### Claim 9 (depends on 1)

The method of claim 1, wherein the signal is one or more selected from the group consisting of an electrical stimulus, a magnetic field, ultrasound, light, and a laser.

### Claim 10

(canceled)

### Claim 11

A method for screening for a pain-relieving substance, comprising:
treating noradrenergic receptors with a candidate substance to confirm whether or not the noradrenergic receptors are inhibited; or
treating GABAA receptors with a candidate substance to confirm whether or not the GABAA receptors are activated.

### Claim 12 (depends on 11)

The method of claim 11, comprising determining the candidate substance as a pain-relieving substance when noradrenergic receptors are inhibited or GABAA receptors are activated by treatment with the candidate substance.

### Claim at position 13

13-30. (canceled)

### Claim 31

A method for relieving or treating pain, the method comprising inhibiting cerebellar glial cells, the locus coeruleus, cerebellar glial cell noradrenergic receptors or cerebellar nuclei.

### Claim 32

The method of 31, wherein the inhibiting comprises a method of injecting a chemogenetic inhibition virus, a method of administering a local antagonist, a method of using shRNA, or a method of administering a GABAA receptor agonist which inhibits the cerebellar nuclei.

### Claim 33

The method of 31, wherein the pain is neuropathic pain, acute pain, neurogenic pain, or a combination thereof.

### Claim 34

The method of 31, wherein the inhibiting the noradrenergic receptor is by administering an alpha-1 adrenergic receptor inhibitor (alpha-1 adrenergic blocking agent).

### Claim 35 (depends on 34)

The method of claim 34, wherein the alpha-1 adrenergic receptor inhibitor (alpha-adrenergic blocking agent) is a substance that inhibits the expression or activity of cerebellar glial cell-specific alpha-1 adrenergic receptors, and
the inhibitor is one or more selected from the group consisting of small interference RNA (siRNA), short hairpin RNA (shRNA), microRNA (microRNA), a ribozyme, a DNAzyme, a peptide nucleic acid (PNA), an antisense oligonucleotide, and an antibody.

### Claim 36 (depends on 35)

The method of claim 35, wherein the alpha-1 adrenergic receptor inhibitor comprises shRNA consisting of SEQ ID NO: 1.

### Claim 37 (depends on 31)

The method of claim 31, wherein the inhibiting the noradrenergic receptor is by administering prazosin,
the inhibiting the cerebellar nuclei is by administering a GABAA receptor agonist, and
the GABAA receptor agonist is muscimol.
